by Clinical Neuropsychologist | Friday, March 8, 2024 | Dementia
Abstract INTRODUCTION Federal policies and guidelines have expanded the return of individual results to participants and expectations for data sharing between investigators and through repositories. Here, we report investigators’ and study participants’ views and...
by Clinical Neuropsychologist | Friday, March 8, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | March 8, 2024 Wiley: Alzheimer’s & Dementia: Table...
by Clinical Neuropsychologist | Friday, March 8, 2024 | Dementia
Abstract BACKGROUND Structural disconnectivity was found to precede dementia. Global white matter abnormalities might also be associated with postoperative delirium (POD). METHODS We recruited older patients (≥65 years) without dementia that were scheduled for major...
by Clinical Neuropsychologist | Thursday, March 7, 2024 | Dementia
Abstract INTRODUCTION Rate of cognitive decline (RCD) in Alzheimer’s disease (AD) determines the degree of impairment for patients and of burden for caretakers. We studied the association of RCD with genetic variants in AD. METHODS RCD was evaluated in 62...
by Clinical Neuropsychologist | Thursday, March 7, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Mari L. DeMarco, Alicia Algeciras‐Schimnich, Melissa M....
by Clinical Neuropsychologist | Wednesday, March 6, 2024 | Dementia
Abstract INTRODUCTION Tau phosphorylated at threonine-217 (pT217-tau) is a novel fluid-based biomarker that predicts onset of Alzheimer’s disease (AD) symptoms, but little is known about how pT217-tau arises in the brain, as soluble pT217-tau is dephosphorylated...
